Scientific Annex
Creatine Supplementation as a Neuroenergetic Adjunct in Obstructive Sleep Apnoea (OSA)
1. Introduction
Obstructive Sleep Apnoea (OSA) is characterised by recurrent upper airway collapse during sleep, resulting in intermittent hypoxia, sleep fragmentation, sympathetic overactivation, and systemic inflammation (Jordan et al., 2014). While Continuous Positive Airway Pressure (CPAP) therapy addresses mechanical airway obstruction, residual daytime cognitive impairment remains common even among treated patients (Bucks et al., 2013).
Emerging evidence suggests that mitochondrial dysfunction and impaired cerebral energy metabolism may contribute to OSA-related neurocognitive deficits (Rosenzweig et al., 2015). Creatine supplementation, through its role in ATP buffering and mitochondrial support, represents a plausible adjunctive neuroenergetic intervention.
This annex evaluates the mechanistic rationale and evidence base for creatine supplementation as a secondary resilience intervention within the Preventive Public Policy (PPP) framework.
2. Pathophysiology of Neurocognitive Impairment in OSA
OSA-induced intermittent hypoxia produces:
Oxidative stress
Neuroinflammation
Impaired cerebral perfusion
Reduced mitochondrial efficiency
Functional MRI studies demonstrate structural and metabolic alterations in frontal and hippocampal regions among untreated OSA patients (Rosenzweig et al., 2013).
Cognitive domains most affected include:
Executive function
Working memory
Sustained attention
Processing speed
These impairments carry economic and safety implications at population scale.
3. The Creatine–Phosphocreatine Energy System
Creatine operates via the phosphocreatine (PCr) system:
Creatine + ATP ⇄ Phosphocreatine + ADP
In high-energy-demand tissues (brain and muscle), phosphocreatine acts as an ATP buffer, stabilising cellular energy availability during metabolic stress (Wyss & Kaddurah-Daouk, 2000).
Supplementation increases brain phosphocreatine concentrations by approximately 5–15% (Dechent et al., 1999)
Potentially enhancing resilience during:
Sleep deprivation
Hypoxic exposure
Cognitive strain
Given that OSA involves intermittent hypoxic episodes, creatine’s bioenergetic role is mechanistically relevant.
4. Evidence from Sleep Deprivation and Cognitive Stress Models
Although OSA-specific RCTs are limited, creatine has been evaluated in sleep-restriction paradigms.
Key Findings:
Improved working memory during sleep deprivation (McMorris et al., 2006)
Reduced mental fatigue (Avgerinos et al., 2018)
Improved reaction time under cognitive load
Potential mood-stabilising effects
Creatine effects appear amplified under conditions of metabolic stress (Rawson & Venezia, 2011).
These findings provide indirect but biologically plausible support for OSA-adjacent use.
5. Dose and Safety Considerations
Standard evidence-based dosing:
Loading phase: 20g/day for 5–7 days
Maintenance phase: 3–5g/day
Higher intakes (10–15g/day) have been studied in short-to-medium-term trials without significant adverse renal effects in healthy individuals (Kreider et al., 2017).
However:
Long-term high-dose data remain limited
Monitoring renal function is advisable
Adequate hydration is required
Within public health framing, conservative maintenance dosing (3–5g/day) is most defensible pending OSA-specific trials.
6. Conceptual Model: Neuroenergetic Resilience in OSA
Creatine does not treat airway obstruction.
However, it may:
Improve daytime alertness
Enhance executive function
Reduce perceived fatigue
Improve occupational performance
Thus, creatine may function as a secondary impairment mitigation strategy, complementing:
Mechanical correction (CPAP)
Metabolic correction (anti-inflammatory diet)
Weight management
This layered intervention reflects systems biology rather than siloed treatment.
7. Fiscal Relevance within PPP Framework
Creatine is:
Low cost (£40–£80 annually bulk supply)
Widely available
Non-patent restricted
Low systemic risk under standard dosing
If adjunctive use improves:
Workplace productivity
Cognitive efficiency
CPAP adherence
Accident reduction
Then population-level cost-benefit ratios may be favourable, even if effect sizes are modest.
Within the PPP doctrine, such low-cost resilience interventions warrant pilot evaluation.
8. Research Gaps
Critical gaps include:
No large RCTs examining creatine in diagnosed OSA populations
Limited dose-response data specific to sleep fragmentation
No long-term cognitive outcome studies in OSA
Future research should assess:
Cognitive endpoints (executive function, reaction time)
Daytime somnolence scales
CPAP adherence rates
Inflammatory biomarker interaction
9. Conclusion
OSA is increasingly understood as a multisystem disorder involving mechanical obstruction, metabolic dysregulation, and neuroenergetic stress.
Creatine supplementation represents:
A mechanistically plausible
Low-cost
Neuroprotective adjunct
While not a replacement for primary treatment, it may enhance cognitive resilience and functional recovery in affected individuals.
Within the Preventive Public Policy framework, creatine merits structured pilot evaluation rather than dismissal, particularly given its safety profile and economic accessibility.
References (Harvard Style)
Avgerinos, K.I. et al. (2018) ‘Effects of creatine supplementation on cognitive function’, Experimental Gerontology, 108, pp. 166–173.
Bucks, R.S. et al. (2013) ‘Neurocognitive function in obstructive sleep apnoea’, Journal of Sleep Research, 22(5), pp. 589–597.
Dechent, P. et al. (1999) ‘Increase of total creatine in human brain after oral supplementation’, American Journal of Physiology, 277, pp. R698–R704.
Jordan, A.S., McSharry, D.G. and Malhotra, A. (2014) ‘Adult obstructive sleep apnoea’, The Lancet, 383(9918), pp. 736–747.
Kreider, R.B. et al. (2017) ‘International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation’, Journal of the International Society of Sports Nutrition, 14(18).
McMorris, T. et al. (2006) ‘Creatine supplementation and cognitive performance in sleep deprivation’, Psychopharmacology, 185(1), pp. 93–103.
Rawson, E.S. and Venezia, A.C. (2011) ‘Use of creatine in the elderly and evidence for effects on cognitive function’, Amino Acids, 40, pp. 1349–1362.
Rosenzweig, I. et al. (2013) ‘Brain structural changes in obstructive sleep apnoea’, European Respiratory Journal, 42(6), pp. 1618–1629.
Rosenzweig, I. et al. (2015) ‘Sleep apnoea and the brain’, The Lancet Respiratory Medicine, 3(5), pp. 404–414.
Wyss, M. and Kaddurah-Daouk, R. (2000) ‘Creatine and creatinine metabolism’, Physiological Reviews, 80(3), pp. 1107–1213.